MediWound (NASDAQ:MDWD - Get Free Report) was upgraded by analysts at StockNews.com to a "sell" rating in a research report issued to clients and investors on Tuesday.
Separately, HC Wainwright reissued a "buy" rating and issued a $28.00 price target on shares of MediWound in a report on Friday, March 22nd.
Get Our Latest Stock Report on MediWound
MediWound Trading Down 3.2 %
Shares of MDWD traded down $0.61 during midday trading on Tuesday, reaching $18.61. The stock had a trading volume of 54,804 shares, compared to its average volume of 69,258. MediWound has a one year low of $7.10 and a one year high of $19.80. The firm has a market cap of $176.61 million, a PE ratio of -24.17 and a beta of 0.93. The firm has a 50 day simple moving average of $15.57 and a 200-day simple moving average of $12.15.
MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. The firm had revenue of $5.34 million during the quarter, compared to analysts' expectations of $5.33 million. MediWound had a negative net margin of 35.94% and a negative return on equity of 20.22%. As a group, research analysts forecast that MediWound will post -1.93 EPS for the current fiscal year.
Institutional Trading of MediWound
Several institutional investors and hedge funds have recently modified their holdings of the business. Yelin Lapidot Holdings Management Ltd. raised its stake in MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company's stock worth $1,276,000 after acquiring an additional 39,348 shares in the last quarter. Sargent Investment Group LLC increased its position in MediWound by 7.0% during the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company's stock worth $1,111,000 after purchasing an additional 7,125 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in MediWound by 7.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company's stock valued at $1,214,000 after purchasing an additional 6,200 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors.
About MediWound
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Featured Articles
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
